Pharmaceutical Business Review feed
Pharmaceutical Business Review - News
Updated: 1 hour 6 sec ago
Trillium Therapeutics, a wholly owned subsidiary of Stem Cell Therapeutics, has completed dosing of patients with interstitial cystitis/bladder pain syndrome (IC/BPS) in first phase study of TTI-1612.
Evotec and Harvard University have entered into research collaboration to develop new class of antibacterials.
Helsinn Healthcare and Vifor Pharma have signed a licensing and distribution deal for netupitant-palonosetron fixed dose combination (NEPA) in Switzerland, France, Spain, Portugal, the Netherlands, Belgium and Luxembourg.
Janssen Biotech has announced the FDA approval of Simponi (golimumab) to treat moderately to severely active ulcerative colitis (UC) in adult patients with corticosteroid dependence or an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.
The US FDA has approved Xofigo (radium Ra 223 dichloride) for the treatment of symptomatic late-stage (metastatic) castration-resistant prostate cancer spread to bones but not to other organs in men.
Canada-based pharmaceutical company Nuvo Research has received US Patent relating to compositions and methods of using WF10 and new derivative formulations for the treatment of allergic asthma, allergic rhinitis and atopic dermatitis.
Roche Group member Genentech and Astellas Pharma US announced that the US Food and Drug Administration (FDA) has cleared Tarceva (erlotinib).
Natera and Echevarne have entered into a distribution agreement under which Echevarne will offer Natera's non-invasive prenatal screening test (NIPT), Panorama, in Spain.
Soligenix has begun Phase 1 study with SGX203 for the treatment of paediatric Crohn's disease.
The US FDA has approved Mylan Pharmaceuticals' abbreviated new drug application (ANDA) for Zolmitriptan tablets, 2.5mg and 5mg.
Nordion has entered into a contract manufacturing agreement with Navidea Biopharmaceuticals for NAV5001 a diagnostic imaging agent used to detect Parkinsonian Syndromes and Dementia with Lewy Bodies.
Merck Serono and Quintiles have entered into a five-year clinical development agreement for the development and clinical trial execution.
Nanosphere has signed a distribution and collaboration agreement with Hitachi High-Technologies.
OncoMed Pharmaceuticals has commenced Phase 1b/2 trial of anti-cancer stem cell therapeutic OMP-59R5 (Anti-Notch2/3) in small cell lung cancer (SCLC) patients.
Taiwan-based specialty pharmaceutical company TWi Pharmaceuticals has obtained FDA tentative approval for its abbreviated new drug application (ANDA) for Guanfacine Hydrochloride Extended Release tablets 1mg, 2mg, 3mg and 4mg.
Rib-X Pharmaceuticals, Ligand Pharmaceuticals' partner, has commenced Phase 3 trial of a Captisol-enabled intravenous (IV) formulation of delafloxacin to treat acute bacterial skin and skin structure infections (ABSSSI).
AbbVie and Alvine Pharmaceuticals have collaborated to develop investigational oral therapy ALV003 for celiac disease.
Bend Research has announced the expansion of its good manufacturing practice (GMP) analytical capabilities and capacity to support pharmaceutical development.
The Indian government has announced the development of new low-cost vaccine referred to as Rotavac against rotavirus, a diarrhea causative agent leading to a number of childhood deaths in the developing world.
Biopharmaceutical company Actinium Pharmaceuticals has received notice of patent allowance for an application covering the treatment of metastatic solid cancers with alpha emitting isotopes.